149 Fifth Avenue
Suite 500
New York, NY 10010
United States
212 994 8250
https://minktherapeutics.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 31
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Garo H. Armen Ph.D. | Executive Chairman | N/D | N/D | 1953 |
Dr. Jennifer S. Buell Ph.D. | President, CEO & Director | 916,75k | N/D | 1976 |
Dr. Marcus Antonius van Dijk Ph.D. | Chief Scientific Officer | 458,28k | N/D | 1962 |
Ms. Christine M. Klaskin | Treasurer | 29,62k | N/D | 1966 |
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
L'ISS Governance QualityScore di MiNK Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.